Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Total Liabilities (2019 - 2025)

Silence Therapeutics' Total Liabilities history spans 7 years, with the latest figure at $69.1 million for Q4 2025.

  • For Q4 2025, Total Liabilities rose 0.77% year-over-year to $69.1 million; the TTM value through Dec 2025 reached $69.1 million, up 0.77%, while the annual FY2025 figure was $69.1 million, 0.77% up from the prior year.
  • Total Liabilities for Q4 2025 was $69.1 million at Silence Therapeutics, down from $72.7 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $118.2 million in Q4 2021 and bottomed at -$156.8 million in Q1 2024.
  • The 5-year median for Total Liabilities is $71.1 million (2025), against an average of $22.0 million.
  • The largest annual shift saw Total Liabilities decreased 27.99% in 2024 before it soared 157.4% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $118.2 million in 2021, then fell by 15.21% to $100.2 million in 2022, then decreased by 4.91% to $95.3 million in 2023, then fell by 27.99% to $68.6 million in 2024, then grew by 0.77% to $69.1 million in 2025.
  • Per Business Quant, the three most recent readings for SLN's Total Liabilities are $69.1 million (Q4 2025), $72.7 million (Q3 2025), and $71.1 million (Q2 2025).